Tabrecta
Chemical Name | capmatinib |
Dosage Form | Tablets (oral; 150 mg, 200 mg) |
Drug Class | Kinase inhibitors |
System | Respiratory |
Company | Novartis |
Approval Year | 2020 |
Indication
- Indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA approved test.